(Body Protection Compound-157) is a synthetic pentadecapeptide investigated mainly in cells and animal models for effects on tissue repair biology, angiogenesis, and gastrointestinal integrity
Very large vials create tiny low-dose draws and may sit too long after mixing
Acute injuries may be 80-90% healed, while chronic injuries show substantial improvement but often require additional weeks for complete resolution
Emerging human case studies suggest similar efficacy patterns
Marian Irene Escasura, MD: Nothing to disclose E-Posters - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE P2255 - ESOC25-1452 REHABILITATION AND CLINICAL OBSERVATION OF STROKE PATIENTS TO VALIDATE PROGNOSTIC FACTORS OF FUNCTIONAL AND SUBJECTIVE RECOVERY AFTER STROKE (RECOVER-S): INTERIM ANALYSIS OF A MULTICENTER, CROSS-SECTOR, STROKE REHABILITATION COHORT Nurcennet Kaynak 1 , Charlotte Pietrock 1 , Valentin Kennel 1 , Martin Ebinger 2 , Bruno-Marcel MacKert 3 , Sven Schpe 4 , Robert Lindenberg 5 , Gerhard Jan Jungehlsing 6 , Felix Schmidt 7 , Ursula Mller-Werdan 8 , Nils Banthien 9 , Matthias Endres 1 , Torsten Rackoll 1 , Alexander Nave 1 1 Charit Universittsmedizin Berlin, Center for Stroke Research Berlin (CSB), Department of Neurology, Berlin, Germany, 2 Medical Park Berlin Humboldtmhle, Berlin, Germany, 3 Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany, 4 Krankenhaus Bethel Berlin, Berlin, Germany, 5 ZAR Zentrum fr ambulante Rehabilitation Berlin Gartenstrae, Berline, Germany, 6 Jdisches Krankenhaus Berlin, Berlin, Germany, 7 Brandenburgklinik, Berlin, Germany, 8 Evangelisches Geriatriezentrum Berlin (EGZB), Berlin, Germany, 9 Vivantes Rehabilitation GmbH, Berlin, Germany Background and Aims: Stroke rehabilitation is crucial in optimizing outcomes following stroke
